FDA Panel Suggests Adding Pediatric Risk Warning To GSK’s Serevent Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Pediatric Advisory Committee also suggests changes in Cephalon’s Provigil label that exclude use in pediatric population.
You may also be interested in...
FDA Expert Panel To Review Serevent, Foradil Safety; Asthma-Related Deaths A Concern
Advisory committee meets on the benefits and risks of the beta-2 agonist class for the third time in three years.
FDA Expert Panel To Review Serevent, Foradil Safety; Asthma-Related Deaths A Concern
Advisory committee meets on the benefits and risks of the beta-2 agonist class for the third time in three years.
FDA Uncertain About GSK’s Serevent Pediatric Risk-Benefit Ratio
Pediatric Advisory Committee will review adverse events data for the asthma treatment Serevent and the adequacy of pediatric risk information in the drug’s labeling.